Dr. Rebecca Anne Deal, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 707 Sheridan Ave, Cody, WY 82414 Phone: 307-527-7501 |
Thomas H Etter, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 902 Blackburn St, Cody, WY 82414 Phone: 307-296-1355 Fax: 307-586-5464 |
James L Johnson Ii, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 125 W Yellowstone Ave, Cody, WY 82414 Phone: 307-527-7129 Fax: 307-587-7394 |
Charles G Welch, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1613 Stampede Ave, Suite A, Cody, WY 82414 Phone: 307-587-9800 Fax: 307-587-9830 |
Dr. William S Evans, MD Surgery - Vascular Surgery Medicare: Not Enrolled in Medicare Practice Location: 424 Yellowstone Ave, Ste 2d, Cody, WY 82414 Phone: 307-578-2947 Fax: 307-578-2492 |
News Archive
The British Medical Association will today (Thursday 3 June 2004) publish an A to Z of Doctors Making a Difference. This UK-wide report illustrates how doctors are leading developments to increase patient care, improve access to services and enhance the patient experience.
Researchers have generated a new type of human stem cell that can develop into numerous types of specialized cells, including functioning pancreatic beta cells that produce insulin. Called endodermal progenitor (EP) cells, the new cells show two important advantages over embryonic stem cells and induced pluripotent stem cells: they do not form tumors when transplanted into animals, and they can form functional pancreatic beta cells in the laboratory.
More than 63 percent of American children and 55 percent of Americans live in "asset" poverty, meaning they have few or no assets to rely on in the event of a financial shock such as a job loss, a medical crisis or the recent federal government shutdown, new research from Oregon State University indicates.
A routine doctor's visit for a sore throat brought more than $28,000 in charges for one New York City woman in our latest "Bill of the Month" installment.
TenX Biopharma, Inc. announced today that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients (ClinicalTrials.gov identifier: NCT00127881). The trial enrollment was suspended in October 2008 while Genmab was seeking a out-license agreement to further develop the compound. TenX Biopharma acquired global rights to zanolimumab in February, 2010 from Genmab.
› Verified 2 days ago